Data Boosts AERI, FDA Panel Snubs SPPI, D-Day For ACRX Today, VTAE Abuzz

Shares of Aerie Pharmaceuticals Inc. (AERI) were up 61% in extended trading on Wednesday, following positive topline data from the first phase III trial of its investigational glaucoma drug Roclatan.

from RTT - Biotech http://ift.tt/2cWXr1P
via IFTTT